Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 379 participants.
Also called NCT02009865
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 379 participants
- Sponsor
- Registry
-
NCT02009865
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Czechia, Denmark, Hungary, Netherlands, Russia
- Registry status
- Completed
Technical summary
Registry record NCT02009865. Randomized; double masking; primary purpose treatment. Start 2013-12-16 (actual); primary completion 2014-12-23 (actual). Results posted on 2016-01-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
- Acronym
- EVOLVEII
- Condition
- Hypertriglyceridemia
- Intervention (Drug)
- Epanova
- Intervention (Drug)
- Olive Oil
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct02009865- Content hash
52805bed53ab5c9ad2ca531f9851449482959d6b0f962ef79d97e2d64c045a08